Sign In
Buy RYTM
$99.25
-6.49 (-6.14%)
At Close: Jul 31, 2026
BOSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic
Rhythm Pharmaceuticals Announces Expanded Access Program for Setmelanotide for Patients with Bardet-Biedl Syndrome
04:01pm, Wednesday, 08'th Sep 2021
Expanded access program may allow access for eligible patients in the United States who have no authorized treatment options Expanded access program may allow access for eligible patients in the Unite
Rhythm Pharmaceuticals Announces CMO Transition
04:01pm, Thursday, 02'nd Sep 2021
-- Linda Shapiro Manning, M.D., Ph.D., promoted to Chief Medical Officer, effective Sept. 10 -- -- CMO Murray Stewart, M.D., to transition to Senior Medical Advisor -- BOSTON, Sept. 02, 2021 (GLOBE NE
Rhythm Pharmaceuticals to Present at Morgan Stanley 19th Annual Global Healthcare Conference
08:00am, Thursday, 02'nd Sep 2021
BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic
Rhythm Pharmaceuticals to Present at the 59th Annual ESPE Meeting
07:45am, Thursday, 12'th Aug 2021
Company announces acceptance of seven abstracts with data from multiple clinical trials evaluating setmelanotide for rare genetic diseases of obesity Company announces acceptance of seven abstracts wi
Rhythm Pharmaceuticals, Inc. (RYTM) Upgraded to Buy: Here's Why
01:42pm, Thursday, 05'th Aug 2021
Rhythm Pharmaceuticals, Inc. (RYTM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Rhythm Pharmaceuticals, Inc. (RYTM) CEO David Meeker on Q2 2021 Results - Earnings Call Transcript
02:42pm, Tuesday, 03'rd Aug 2021
Rhythm Pharmaceuticals, Inc. (RYTM) CEO David Meeker on Q2 2021 Results - Earnings Call Transcript
Rhythm Pharmaceuticals Reports Second Quarter 2021 Financial Results
07:01am, Tuesday, 03'rd Aug 2021
-- Received European Commission authorization of IMCIVREE for treatment of obesity and control of hunger associated with POMC, PCSK1 and LEPR deficiencies -- -- Setmelanotide selected for evaluation
-- Pivotal Phase 3 EMANATE trial planned in patients with heterozygous POMC, PCSK1 or LEPR, and SRC1 or SH2B1 deficiency obesities -- -- EMANATE, as well as Phase 2 DAYBREAK trial evaluating setmelano
Rhythm Pharmaceuticals Announces Collaborative Research Agreement with Clinical Registry Investigating Bardet-Biedl Syndrome
04:01pm, Wednesday, 28'th Jul 2021
Population study to focus on natural history of weight gain, hyperphagia and quality of life in patients with Bardet-Biedl syndrome Population study to focus on natural history of weight gain, hyperph
Rhythm Pharmaceuticals to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
08:00am, Tuesday, 27'th Jul 2021
BOSTON, July 27, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic
First-ever authorized treatment option in the European Union for these rare genetic diseases of obesity First-ever authorized treatment option in the European Union for these rare genetic diseases of
European Commission decision anticipated in July European Commission decision anticipated in July
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Surpass Estimates
12:01pm, Monday, 03'rd May 2021
Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 4600.00% and -99.97%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for t
7 Beaten Down Stocks with Significant Insider Buying
02:16pm, Friday, 09'th Apr 2021
Insider buying could be a bullish sign for a stock. Insiders may sell their shares for many reasons.
